Key Updates in IgA Nephropathy at ERA 2025, with Chee Kay Cheung, MBChB, PhD

In this special edition of Kidney Compass, Shikha Wadhwani sits down with Chee Kay Cheung, MBChB, PhD, of the University of Leicester, on the floor at the 62nd European Renal Association (ERA 2025) Congress to reflect on how far IgA nephropathy (IgAN) treatment has come—from what used to feel like “tumbleweeds” in nephrology to a pipeline packed with promising therapies. At the top of the conversation: the rise of B-cell modulating therapies targeting APRIL and BAFF. Cheung highlights the interim results from the global phase 3 VISIONARY trial of sibeprenlimab, an APRIL inhibitor that achieved a 51.2% placebo-adjusted reduction in proteinuria at 9 months—the largest seen in any IgAN phase 3 study to date. Safety data were encouraging, with low discontinuation rates and a favorable overall profile. Also on the radar: new long-term data from zigakibart, another anti-APRIL antibody, and promising topline results from atacicept, which targets both APRIL and BAFF. While head-to-head compa